Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL437807 | 1.00 | MEN1 (0.35) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL18334616 | 1.00 | MEN1 (0.35) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL439321 | 1.00 | MEN1 (0.35) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL5272793 | 0.97 | MEN1 (0.34) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL167529 | 0.94 | MEN1 (0.38) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL18104058 | 0.93 | MEN1 (0.40) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL7717187 | 0.91 | MEN1 (0.36) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL7709080 | 0.90 | MEN1 (0.38) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL169764 | 0.90 | MEN1 (0.42) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL14134777 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781452-B2 | such as 5-(4-Fluorophenoxy)-2-(((4-methoxy-3-methyl-2-pyridinyl)methyl)sulfinyl)-3H-imidazo[4,5-b]pyridine, useful as a gastric acid secretion inhibitor, for the treatment of gastroesophageal reflux or ulcers; antisecretory agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| EP-1737862-A4 | IMIDAZOPYRIDINE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2007-11-28 | — | — | EP | disclosed |
| EP-1737862-A1 | IMIDAZOPYRIDINE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-01-03 | — | — | EP | disclosed |
| US-20060167041-A1 | such as 5-(4-Fluorophenoxy)-2-(((4-methoxy-3-methyl-2-pyridinyl)methyl)sulfinyl)-3H-imidazo[4,5-b]pyridine, useful as a gastric acid secretion inhibitor, for the treatment of gastroesophageal reflux or ulcers; antisecretory agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20050272764-A1 | Imidazopyridine compound | EISAI CO., LTD. | 2005-12-08 | — | — | US | disclosed |
| WO-2005103049-A1 | IMIDAZOPYRIDINE COMPOUND | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272764-A1 | Imidazopyridine compound | H1-3, KCNH2, H1-4 | MEN1 416/4885MAPT 2665/4885KMT2A 657/4885 |
| US-20060167041-A1 | such as 5-(4-Fluorophenoxy)-2-(((4-methoxy-3-methyl-2-pyridinyl)methyl)sulfinyl)-3H-imidazo[4,5-b]pyridine, useful as a gastric acid secretion inhibitor, for the treatment of gastroesophageal reflux or ulcers; antisecretory agents | HRH2, HRH4, GRPR | MEN1 1845/4885MAPT 4820/4885KMT2A 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.